Concord Biotech surged over 5% to around ₹1,340 after receiving USFDA approval for Tofacitinib Tablets. The Jhunjhunwala family holds a 24.1% stake, equivalent to 2.52 crore shares. With the stock gaining about ₹61 per share, the family's holding recorded a notional gain of nearly ₹153.72 crore in early trade on June 10, 2026.